Profile data is unavailable for this security.
About the company
Iovance Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company develops and delivers tumor infiltrating lymphocyte (TIL), therapies for patients with solid tumor cancers. Its lead product candidate, Amtagvi (lifileucel), is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor. The Company also marketing Proleukin (aldesleukin), aninterleukin-2, or IL-2, product used in the Amtagvi treatment regimen. Its development pipeline includes multicenter trials of TIL cell therapies in additional treatment settings for solid tumor cancers. Amtagvi and Proleukin are part of a treatment regimen that also includes lymphodepletion. The Company is also developing next generation therapies using TIL, such as genetically modified TIL cell therapy.
- Revenue in USD (TTM)1.90m
- Net income in USD-449.64m
- Incorporated2017
- Employees557.00
- LocationIovance Biotherapeutics Inc825 INDUSTRIAL ROAD, 4TH FLOORSAN CARLOS 94070United StatesUSA
- Phone+1 (650) 260-7120
- Fax+1 (302) 697-4597
- Websitehttps://www.iovance.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Recursion Pharmaceuticals Inc | 46.24m | -354.11m | 2.16bn | 500.00 | -- | 5.38 | -- | 46.73 | -1.62 | -1.62 | 0.2112 | 1.69 | 0.078 | -- | 19.86 | 92,470.00 | -59.76 | -- | -69.49 | -- | 10.66 | -- | -765.90 | -- | -- | -- | 0.0028 | -- | 11.88 | -- | -36.99 | -- | -- | -- |
| Maravai Lifesciences Holdings Inc | 274.10m | -131.04m | 2.17bn | 570.00 | -- | 5.28 | -- | 7.91 | -0.9917 | -0.9917 | 2.08 | 1.63 | 0.1458 | 2.93 | 5.90 | 421,690.80 | -8.49 | 12.67 | -11.29 | 15.46 | 44.03 | 74.79 | -58.27 | 37.32 | 10.47 | -2.02 | 0.4169 | 0.00 | -67.28 | 18.47 | -154.05 | -- | 78.56 | -- |
| Celldex Therapeutics, Inc. | 6.07m | -144.88m | 2.18bn | 160.00 | -- | 2.59 | -- | 358.32 | -2.84 | -2.84 | 0.1182 | 12.72 | 0.0102 | -- | 3.05 | 37,950.00 | -24.28 | -29.65 | -25.16 | -31.42 | -- | -- | -2,385.97 | -1,747.94 | -- | -- | 0.00 | -- | 192.02 | -6.32 | -25.91 | -- | 17.46 | -- |
| Deciphera Pharmaceuticals Inc | 174.91m | -190.42m | 2.21bn | 355.00 | -- | 6.65 | -- | 12.65 | -2.21 | -2.21 | 2.03 | 3.85 | 0.3607 | 0.2287 | 6.35 | 492,704.20 | -39.26 | -44.54 | -47.45 | -52.24 | 96.95 | -- | -108.87 | -245.88 | 3.94 | -- | 0.00 | -- | 21.87 | -- | -8.95 | -- | -7.11 | -- |
| Intellia Therapeutics Inc | 52.60m | -485.50m | 2.23bn | 526.00 | -- | 2.15 | -- | 42.35 | -5.37 | -5.37 | 0.5827 | 10.76 | 0.0393 | -- | 2.55 | 100,007.60 | -36.27 | -31.34 | -39.21 | -34.53 | -- | -- | -922.94 | -654.71 | -- | -- | 0.00 | -- | -30.40 | 3.57 | -1.48 | -- | 17.08 | -- |
| Vera Therapeutics Inc | 0.00 | -94.30m | 2.25bn | 55.00 | -- | 6.34 | -- | -- | -2.04 | -2.04 | 0.00 | 6.49 | 0.00 | -- | -- | 0.00 | -29.99 | -- | -31.92 | -- | -- | -- | -- | -- | -- | -- | 0.124 | -- | -- | -- | -7.79 | -- | -- | -- |
| Vericel Corp | 207.78m | 451.00k | 2.28bn | 314.00 | 4,900.63 | 9.71 | 421.67 | 10.96 | 0.0096 | 0.0096 | 4.35 | 4.82 | 0.6684 | 4.38 | 4.71 | 661,719.80 | 0.1451 | -3.07 | 0.1621 | -3.50 | 69.50 | 67.87 | 0.2171 | -4.49 | 4.83 | -- | 0.0007 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| Iovance Biotherapeutics Inc | 1.90m | -449.64m | 2.33bn | 557.00 | -- | 3.42 | -- | 1,222.80 | -1.82 | -1.82 | 0.0077 | 2.43 | 0.0023 | -- | -- | 3,418.31 | -53.07 | -51.47 | -59.00 | -57.56 | -846.22 | -- | -23,615.70 | -137,873.80 | 4.42 | -- | 0.0015 | -- | -- | -- | -12.16 | -- | 79.44 | -- |
| Geron Corp | 520.00k | -201.40m | 2.37bn | 141.00 | -- | 6.81 | -- | 4,562.56 | -0.3464 | -0.3464 | 0.0009 | 0.5876 | 0.0012 | -- | 0.3225 | 3,687.94 | -44.41 | -51.32 | -54.44 | -64.90 | -- | -- | -38,729.81 | -19,949.13 | -- | -- | 0.1935 | -- | -60.23 | -25.97 | -29.76 | -- | 120.29 | -- |
| CG Oncology Inc | 539.00k | -72.33m | 2.40bn | 61.00 | -- | 4.22 | -- | 4,450.92 | -1.13 | -1.13 | 0.0084 | 8.54 | -- | -- | -- | 8,836.07 | -- | -- | -- | -- | -- | -- | -10,551.39 | -- | -- | -- | 0.00 | -- | 6.81 | -- | -54.83 | -- | -- | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.43bn | 64.00 | -- | 3.70 | -- | 332.79 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| ADMA Biologics Inc | 283.18m | -3.64m | 2.43bn | 624.00 | -- | 15.82 | 509.91 | 8.59 | -0.0204 | -0.0204 | 1.23 | 0.6632 | 0.8188 | 0.9923 | 7.44 | 453,808.40 | -1.05 | -24.80 | -1.21 | -28.00 | 40.13 | 17.40 | -1.29 | -51.31 | 1.86 | 2.19 | 0.4598 | -- | 67.59 | 72.34 | 57.15 | -- | 18.91 | -- |
| Rhythm Pharmaceuticals Inc | 91.93m | -273.87m | 2.43bn | 226.00 | -- | 39.52 | -- | 26.48 | -4.62 | -4.62 | 1.57 | 1.01 | 0.3042 | 1.53 | 8.06 | 406,747.80 | -90.64 | -47.21 | -108.65 | -52.84 | 88.37 | -- | -297.93 | -681.38 | 4.20 | -139.42 | 0.6355 | -- | 227.56 | -- | -1.97 | -- | -42.10 | -- |
| Fortrea Holdings Inc | 3.01bn | -100.60m | 2.45bn | 16.00k | -- | 1.54 | -- | 0.8132 | -1.13 | -1.37 | 33.82 | 17.81 | 0.7036 | -- | 3.10 | 167,050.00 | -2.35 | -- | -2.84 | -- | 16.64 | -- | -3.35 | -- | -- | 0.2534 | 0.5035 | -- | 0.4167 | -- | -101.76 | -- | -- | -- |
| Novocure Ltd | 525.66m | -192.74m | 2.49bn | 1.45k | -- | 6.93 | -- | 4.74 | -1.81 | -1.81 | 4.92 | 3.34 | 0.4579 | 3.57 | 7.51 | 361,774.90 | -16.79 | -7.74 | -19.40 | -8.95 | 74.82 | 77.22 | -36.67 | -14.69 | 5.99 | -- | 0.6132 | -- | -5.30 | 15.47 | -123.75 | -- | 32.19 | -- |
Data as of Jun 07 2024. Currency figures normalised to Iovance Biotherapeutics Inc's reporting currency: US Dollar USD
38.03%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Mar 2024 | 24.53m | 8.78% |
| Perceptive Advisors LLCas of 31 Mar 2024 | 19.27m | 6.90% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 17.56m | 6.29% |
| Avoro Capital Advisor LLCas of 31 Mar 2024 | 11.70m | 4.19% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 10.40m | 3.72% |
| Geode Capital Management LLCas of 31 Mar 2024 | 5.51m | 1.97% |
| Artisan Partners LPas of 31 Mar 2024 | 5.14m | 1.84% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Mar 2024 | 5.12m | 1.83% |
| Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 3.51m | 1.26% |
| Voloridge Investment Management LLCas of 31 Mar 2024 | 3.49m | 1.25% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
